LifeMD rises on collaboration for improved access to menopause medication
** Shares of telehealth service provider LifeMD LFMD.O
rise 2.3% to $4.41, set to snap a 4-day losing streak
** Co says it is partnering with Virginia-based private
company Ascend Therapeutics to provide telehealth services to
improve access to EstroGel 0.06%
** EstroGel is an FDA approved gel that can help manage some
of the symptoms of menopause
** Including session gains, shares have more than doubled
YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
Recent news on LifeMD
See all newsLifeMD Q1 revenue beats estimates on record telehealth subscriber additons
Brief: LifeMD Q1 Adjusted EBITDA USD -4.5 Million Vs. IBES Estimate USD -4.66 Million
LifeMD rises after adding new daily obesity pill to weight management program
Novo Nordisk to launch discounted Wegovy subscriptions for self-pay patients in US (updated)
Novo Nordisk to launch discounted Wegovy subscriptions for self-pay patients in US